Document › Details
GlaxoSmithKline plc. (3/2/15). "Press Release: GSK Completes Major Three-part Transaction with Novartis. £4 Billion to Be Returned to Shareholderson 6 May 2015". London.
GlaxoSmithKline plc (LSE/NYSE: GSK) announces that its three-part transaction with Novartis has completed today. As a result of this transaction, GSK has acquired Novartis’s global Vaccines business (excluding influenza vaccines) for an initial cash consideration of $5.25 billion; has created a new world-leading Consumer Healthcare joint venture with Novartis in which GSK will have majority control and an equity interest of 63.5%; and has divested its Oncology business for an aggregate cash consideration of $16 billion.
The net after tax proceeds of the transaction received by GSK today are estimated to be $7.8 billion. This reflects the full consideration of $16 billion paid today by Novartis for GSK’s Oncology portfolio and related assets. Under the terms of the transaction, up to $1.5 billion of that purchase price may have to be returned to Novartis if certain conditions relating to the COMBI-d Trial are not met. Following the positive results from this study announced on 6 February 2015, GSK believes these conditions will be satisfied.
As a result, following today’s completion, GSK plans to use the transaction proceeds to fund the full amount of the previously announced capital return of £4 billion to shareholders. Subject to shareholder approval, the capital return is expected to be implemented through a B share scheme, which will provide capital treatment for all UK tax-resident shareholders. Further details on the capital return will be sent to shareholders in due course.
In light of the timing of closing the transaction, the Company intends to report its first quarter results for 2015 and hold an Investor Meeting on 6 May 2015, at which it will provide 2015 earnings guidance and profile the medium and long-term shape and opportunities for the enlarged Group.
Sir Andrew Witty, CEO, GSK said: “Completion of this transaction represents a major step forward in the Group’s strategy to create a stronger and more balanced set of businesses across Pharmaceuticals, Consumer Healthcare and Vaccines. We will now be focused on rapidly implementing our integration plans to realise the growth and synergy opportunities we see in the new Consumer Healthcare and Vaccines businesses. We look forward to sharing more details of this with our shareholders on 6 May.”
GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.
Whilst completion of the transaction with Novartis has taken place today, there are certain jurisdictions in which the transfer of relevant assets to or by GSK will only take place following receipt of additional market-specific approvals or other matters relevant to those jurisdictions. The arrangements in relation to these jurisdictions are considered immaterial in the context of the transaction.
Terms defined in GSK's shareholder circular of 20 November 2014 have the same meaning where used in this announcement. [ http://www.gsk.com/media/560424/gsk-novartis-circular.pdf ]
Information regarding forward-looking statements
This announcement includes statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes”, “estimates”, “plans”, “projects”, “anticipates”, “expects”, “intends”, “may”, “will”, or “should” or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this announcement and include, but are not limited to, statements regarding GSK’s intentions, beliefs or current expectations concerning, among other things, GSK’s business, results of operations, financial position, prospects, growth, strategies and the industry in which it operates as well as those of the Novartis businesses that are the subject of the transaction. By their nature, forward-looking statements involve risk and uncertainty because they relate to future events and circumstances. Forward-looking statements are not guarantees of future performance and the actual results of GSK’s operations and financial position, and the development of the markets and the industry in which GSK operates, may differ materially from those described in, or suggested by, the forward-looking statements contained in this announcement. The same applies in respect of the Novartis Businesses that are the subject of the transaction. In addition, even if the results of operations, financial position and the development of the markets and the industry in which GSK operates are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of results or developments in subsequent periods. A number of factors could cause results and developments to differ materially from those expressed or implied by the forward-looking statements including, without limitation, general economic and business conditions, industry trends, competition, changes in regulation, currency fluctuations, changes in its business strategy, political and economic uncertainty and other factors discussed in this announcement.
Forward-looking statements may, and often do, differ materially from actual results. Any forward-looking statements in this announcement speak only as of their respective dates, reflect GSK’s current view with respect to future events and are subject to risks relating to future events and other risks, uncertainties and assumptions relating to GSK’s operations, results of operations and growth strategy. You should specifically consider the factors identified in this document, in addition to the risk factors that may affect GSK’s operations which are described under “Risk Factors” in the Company’s 2014 Annual Report on Form 20-F, which could cause actual results to differ before making any decision in relation to the Transaction as well as those of the Novartis businesses that are the subject of the transaction. Subject to the requirements of the FCA, the London Stock Exchange, the Listing Rules and the Disclosure and Transparency Rules (and/or any regulatory requirements) or applicable law, GSK explicitly disclaims any obligation or undertaking publicly to release the result of any revisions to any forward-looking statements in this announcement that may occur due to any change in GSK’s expectations or to reflect events or circumstances after the date of this announcement.
Record changed: 2016-08-12
More documents for GlaxoSmithKline (GSK) (Group)
-  GlaxoSmithKline GmbH & Co. KG. (3/20/17). "Pressemitteilung: Spatenstich bei GSK in Marburg für eine 162 Mio € Meningokokken-B-Impfstoff-Produktion"....
-  Bruker Corporation. (2/6/17). "Press Release: Bruker Introduces MALDI PharmaPulse 2.0 Solution at SLAS 2017 for 100x Faster Mass Spectrometry-Based, Label-Free Screening in Drug Discovery"....
-  GlaxoSmithKline plc. (9/29/16). "Press Release: GlaxoSmithKline plc Appoints Brian McNamara as CEO of GSK Consumer Healthcare". London....
-  MorphoSys AG. (4/18/16). "Press Release: MorphoSys Licensing Partner GSK Starts Phase 2 Study with GSK3196165 (MOR103) in Hand Osteoarthritis"....
-  CureVac AG. (3/18/16). "Press Release: CureVac Strengthens Supervisory Board to Support Global Growth Opportunities and mRNA Product Expansion". Tübingen....
-  GlaxoSmithKline plc. (3/16/16). "Press Release: GSK and Miltenyi Biotec Establish Cell and Gene Therapy Collaboration"....
-  Medicxi Ventures. (2/3/16). "Press Release: Medicxi Ventures, Formerly Index Ventures Life Sciences, Launches as an Independent Venture Capital Firm and Announces Closing of a €210m Fund including GSK and Johnson & Johnson Innovation". Castres....
-  Novartis AG. (11/17/15). "Press Release: FLAME Study Shows Superiority of Novartis' Ultibro Breezhaler Over Seretide in Reducing COPD Exacerbations". Basel....
-  GlaxoSmithKline plc. (11/3/15). "Press Release: GSK Profiles Innovative R&D Portfolio to Investors. 40 Potential New Medicines and Vaccines". London....
-  Novartis AG. (10/27/15). "Press Release: Novartis Delivered Strong Core Margin Expansion (cc) and Continued to Strengthen the Pipeline in Q3, on Track for Full-year Guidance". Basel....
To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to firstname.lastname@example.org and simply fill the subject line with the word »LSG newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)